Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer

Protocol No
NRG-CC009
Principal Investigator
Joseph Bovi
Phase
III
Summary
This study is being done to answer the following question: Will high dose radiation therapy delivered only to the small areas of brain cancer and avoiding the surrounding normal brain tissue, called stereotactic radiosurgery (SRS), decrease side effects related to memory and thinking compared to radiation to the entire brain, called whole-brain radiation therapy (WBRT), that avoids the hippocampus but treats all of the brain tissue along with a drug that helps preserve memory and thinking called memantine? For patients with brain metastases from small-cell lung cancer, WBRT avoids the memory zone in the brain called the hippocampus along with a drug that helps preserve memory and thinking called memantine. At the time of the development of this study, there have been no randomized clinical trials comparing WBRT and SRS approaches in patients with small-cell lung cancer. We are doing this study because we want to find out if the SRS approach is better.
Description
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
Participating Institutions
Drexel Town Center
Froedtert Hospital
Froedtert West Bend Hospital
Froedtert Menomonee Falls Hospital
Status
OPEN TO ACCRUAL
Sub Category